Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics for Routine F/U and Home F/U patients according to randomization group in the original RCT

From: Attrition in longitudinal randomized controlled trials: home visits make a difference

  ROUTINE F/U, N=187 HOME F/U, N=61
% unless otherwise indicated % unless otherwise indicated
ALL N=187 LOW MAP N=97 (52%) HIGH MAP N=90 (48%) ALL N=61 LOW MAP N=27 (44%) HIGH MAP N=34 (56%)
Demographic       
Age, mean years (SD) 65.2 (9.3) 65.2 (10.1) 65.3 (8.4) 67.7 (9.5) 70.0 (9.5) 65.9 (9.3)
75 years and older 13.9 16.5 11.1 29.5 40.7 20.6
Male 78.6 78.3 78.9 83.6 78.8 88.2
Caucasian 95.6 94.6 96.6 98.3 96.3 100
College education or higher 48.4 50.5 46.0 44.8 41.7 47.1
Married 73.3 73.2 73.3 77.0 63.0 88.2*
Cardiac and Neurologic History       
Cardiac symptom duration, mean years (SD) 5.0 (7.1) 5.3 (7.6) 4.7 (6.7) 5.7 (8.6) 5.6 (8.4) 5.9 (8.8)
Current and former smokers 72.7 71.1 74.4 78.7 81.5 76.5
Canadian cardiovascular class       
  I 18.7 19.6 17.8 13.1 14.8 11.8
  II 22.5 24.7 20.0 27.9 25.9 29.4
  III 12.3 11.3 13.3 16.4 29.6 5.9
  IV 27.8 30.9 24.4 16.4 14.8 17.7
Ejection Fraction, mean (SD) 48.5 (12.1) 49.3 (12.1) 47.6 (12.2) 47.4 (13.9) 47.2 (15.1) 47.6 (13.0)
Left main disease 13.9 14.4 13.3 11.5 22.2 2.9*
Previous MI 42.3 36.1 48.9 44.3 44.4 44.1
Congestive heart failure 10.7 10.3 11.1 11.5 14.8 8.8
COPD/Asthma 10.7 6.2 15.6* 6.6 7.4 5.8
Peripheral vascular disease 21.9 23.7 20.0 16.4 22.2 11.8
CVA 11.8 8.3 15.6 8.2 7.4 8.8
Charlson Comorbidity Score       
  0-1 58.8 58.8 58.9 54.1 48.1 58.8
  2-3 27.8 27.8 27.8 36.1 44.4 29.4
  ≥ 4 13.4 13.4 13.3 9.8 7.4 11.8
Hypertension 49.2 43.3 55.6 59.0 59.3 58.8
Dialysis 1.6 2.1 1.1 0 0 0
Renal dysfunction 5.9 6.2 5.6 4.9 3.7 5.9
Diabetes 20.3 23.7 16.7 19.7 18.5 20.6
  End organ damage 44.7 43.5 46.7 33.3 40.0 28.6
Medications       
Diuretics 16.0 16.5 15.6 27.9 33.3 23.5
Calcium channel blockers 62.6 60.8 64.4 63.9 55.6 70.6
Nitrates 55.1 60.8 48.9 52.5 70.4 38.2*
Beta blockers 57.8 55.7 60.0 52.5 48.2 55.9
Ace inhibitors 16.6 17.5 15.6 16.4 22.2 11.8
Neurocognitive tests       
Ammons IQ Test, mean (SD) 106.6 (14.4) 107.2 (15.5) 106.0 (13.3) 102.3 (12.2) 100.2 (10.5) 103.9 (13.2)
Linguistic Function       
  Boston Naming Test, median (range) 26.0 (8–30) 26.0 (8–30) 26.0 (11–30) 25 (9–30) 25 (12–30) 25 (9–30)
  Controlled Word Association, mean (SD) 38.4 (13.4) 38.4 (13.5) 38.4 (13.3) 35.1(12.6) 34.2 (11.4) 35.7 (13.5)
Memory       
  Benton Visual Recall, mean (SD) 5.2 (2.2) 5.3 (2.1) 5.1 (2.3) 4.6 (2.2) 5.0 (1.9) 4.3 (2.4)
  Benton Recognition, median (range) 8 (3–10) 8 (3–10) 8 (4–10) 7.5 (0–10) 7 (3–10) 8 (0–10)
  Mattis-Kovner Recall, mean (SD) 10.7 (3.4) 10.9 (3.4) 10.6 (3.4) 9.9 (3.6) 9.6 (4.0) 10.3 (3.2)
  Mattis-Kovner, mean (SD) 2.7 (0–3.9) 2.7 (0–3.9) 2.7 (0–3.9) 2.6 (1.2-3.9) 2.4 (1.3-3.9) 2.7 (1.2-3.9)
  Recognition, median (range)       
Psychomotor function       
  Trails A, median (range) 40 (15–162) 38.5 (15–162) 41 (20–141) 39 (17–217) 39 (19–100) 41.5 (17–217)
  Trails B, median (range) 86 (32–350) 85.0 (32–350) 89.5 (42–320) 104.5 (38–405) 117 (42–405) 92 (38–309)
  Digit Symbol, mean (SD) 42.1 (12.3) 42.7 (13.6) 41.5 (10.7) 38.2 (11.9) 34.7 (12.3) 41.2 (10.9)*
  Digit Span, mean (SD) 14.7 (4.1) 15.2 (4.0) 14.1 (4.1) 14.0 (3.7) 13.3 (3.5) 14.5 (3.8)
  Finger Tapping Dominant, mean (SD) 47.1 (10.6) 47.0 (10.6) 47.2 (10.6) 44.2 (8.4) 45.0 (8.9) 43.5 (8.1)
  Finger Tapping Non-dominant, mean (SD) 42.5 (8.9) 42.1 (9.2) 43.1 (8.7) 40.7 (8.1) 42.0 (8.0) 39.6 (8.2)
  1. *Indicates comparison of High vs. Low MAP p<0.05.